China SXT Pharmaceuticals (NASDAQ:SXTC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of China SXT Pharmaceuticals (NASDAQ:SXTC) from a sell rating to a hold rating in a report issued on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 21st. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, China SXT Pharmaceuticals currently has an average rating of “Sell”.

China SXT Pharmaceuticals Stock Performance

Shares of NASDAQ SXTC opened at $2.78 on Friday. China SXT Pharmaceuticals has a 52 week low of $2.71 and a 52 week high of $8,375,880.00. The firm has a 50-day moving average price of $167.48 and a 200 day moving average price of $15,942.55. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals, Inc is a pharmaceutical company focused on the development, manufacture and sale of traditional Chinese medicine (TCM) products. The company produces herbal formulations intended for use in the treatment and management of various health conditions, as well as products positioned for general wellness and health maintenance.

Its product portfolio includes prescription medicines, over-the-counter medicines and dietary supplements. The company’s offerings are based on traditional Chinese medicinal practices and may be provided in forms such as herbal extracts, pills and other finished formulations.